Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20278 | 0.74 | CTNNB1 (0.31) | KIF11 | |
| SCHEMBL8636682 | 0.73 | — | — | |
| SCHEMBL2665687 | 0.72 | KIF11 (0.41) | KIF11 | |
| SCHEMBL423133 | 0.67 | KIF11 (0.47) | KIF11 | |
| SCHEMBL631735 | 0.66 | KIF11 (0.30) | KIF11 | |
| SCHEMBL27041159 | 0.64 | — | — | |
| SCHEMBL18768657 | 0.63 | KIF11 (0.44) | KIF11 | |
| SCHEMBL2560230 | 0.63 | KIF11 (0.44) | KIF11 | |
| SCHEMBL19563466 | 0.63 | KIF11 (0.53) | KIF11 | |
| SCHEMBL1721979 | 0.63 | KIF11 (0.44) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796250-B2 | Diaryl ureas for diseases mediated by PDGFR | BAYER HEALTHCARE LLC (US) | 2014-08-05 | — | — | US | claimed |
| EP-1636585-B2 | DIARYL UREAS WITH KINASE INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2012-06-13 | — | — | EP | claimed |
| JP-4658037-B2 | — | — | 2011-03-23 | — | — | JP | claimed |
| EP-1599467-B1 | NOVEL CYANOPYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | BAYER HEALTHCARE LLC (US) | 2010-05-19 | — | — | EP | claimed |
| US-7557129-B2 | Cyanopyridine derivatives useful in the treatment of cancer and other disorders | BAYER HEALTHCARE LLC (US) | 2009-07-07 | — | — | US | claimed |
| EP-1636585-B1 | DIARYL UREAS WITH KINASE INHIBITING ACTIVITY | BAYER PHARMACEUTICALS CORP (US) | 2008-01-16 | — | — | EP | claimed |
| EP-1626714-B1 | DIARYL UREAS FOR DISEASES MEDIATED BY PDGFR | BAYER PHARMACEUTICALS CORP (US) | 2007-07-04 | — | — | EP | claimed |
| JP-2007511203-A | — | — | 2007-05-10 | — | — | JP | claimed |
| JP-2006519264-A | — | — | 2006-08-24 | — | — | JP | claimed |
| EP-1636585-A2 | DIARYL UREAS WITH KINASE INHIBITING ACTIVITY | Bayer Pharmaceuticals Corporation (US) | 2006-03-22 | — | — | EP | claimed |
| EP-1626714-A2 | DIARYL UREAS FOR DISEASES MEDIATED BY PDGFR | Bayer Pharmaceuticals Corporation (US) | 2006-02-22 | — | — | EP | claimed |
| EP-1599467-A1 | NOVEL CYANOPYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | Bayer Pharmaceuticals Corporation (US) | 2005-11-30 | — | — | EP | claimed |
| US-20050059703-A1 | Treating, ameliorating, preventing, or modulating restenosis following angioplastic surgery, injure the vascular system; a salt of N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea; intravascular stent is impregnated with the compound to inhibit restenosis | BAYER HEALTHCARE LLC | 2005-03-17 | — | — | US | claimed |
| WO-2005000284-A2 | DIARYL UREAS FOR DISEASES MEDIATED BY PDGFR | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-01-06 | — | — | WO | claimed |
| WO-2004113274-A2 | DIARYL UREAS WITH KINASE INHIBITING ACTIVITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-12-29 | — | — | WO | claimed |
| US-20040235829-A1 | Novel cyanopyridine derivatives useful in the treatment of cancer and other disorders | BAYER HEALTHCARE LLC | 2004-11-25 | — | — | US | claimed |
| WO-2004078747-A1 | NOVEL CYANOPYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-09-16 | — | — | WO | claimed |
| US-20040152903-A1 | 6-chloro-3-pyridylmethylpropylamine derivatives, preparation process thereof and bactericides | KUREHA CORPORATION (JP) | 2004-08-05 | — | — | US | claimed |
| EP-1375483-A1 | 6-CHLORO-3-PYRIDYLMETHYLPROPYLAMINE DERIVATIVES, PREPARATION PROCESS THEREOF AND BACTERICIDES | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 2004-01-02 | — | — | EP | claimed |
| US-8796250-B2 | Diaryl ureas for diseases mediated by PDGFR | BAYER HEALTHCARE LLC (US) | 2014-08-05 | — | — | US | disclosed |
| EP-1599467-B1 | NOVEL CYANOPYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | BAYER HEALTHCARE LLC (US) | 2010-05-19 | — | — | EP | disclosed |
| US-7557129-B2 | Cyanopyridine derivatives useful in the treatment of cancer and other disorders | BAYER HEALTHCARE LLC (US) | 2009-07-07 | — | — | US | disclosed |
| EP-1626714-B1 | DIARYL UREAS FOR DISEASES MEDIATED BY PDGFR | BAYER PHARMACEUTICALS CORP (US) | 2007-07-04 | — | — | EP | disclosed |
| EP-1626714-A2 | DIARYL UREAS FOR DISEASES MEDIATED BY PDGFR | Bayer Pharmaceuticals Corporation (US) | 2006-02-22 | — | — | EP | disclosed |
| EP-1599467-A1 | NOVEL CYANOPYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | Bayer Pharmaceuticals Corporation (US) | 2005-11-30 | — | — | EP | disclosed |
| US-20050059703-A1 | Treating, ameliorating, preventing, or modulating restenosis following angioplastic surgery, injure the vascular system; a salt of N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea; intravascular stent is impregnated with the compound to inhibit restenosis | BAYER HEALTHCARE LLC | 2005-03-17 | — | — | US | disclosed |
| WO-2005000284-A2 | DIARYL UREAS FOR DISEASES MEDIATED BY PDGFR | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-01-06 | — | — | WO | disclosed |
| US-20040235829-A1 | Novel cyanopyridine derivatives useful in the treatment of cancer and other disorders | BAYER HEALTHCARE LLC | 2004-11-25 | — | — | US | disclosed |
| WO-2004078747-A1 | NOVEL CYANOPYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-09-16 | — | — | WO | disclosed |
| US-20040152903-A1 | 6-chloro-3-pyridylmethylpropylamine derivatives, preparation process thereof and bactericides | KUREHA CORPORATION (JP) | 2004-08-05 | — | — | US | disclosed |
| EP-1375483-A1 | 6-CHLORO-3-PYRIDYLMETHYLPROPYLAMINE DERIVATIVES, PREPARATION PROCESS THEREOF AND BACTERICIDES | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 2004-01-02 | — | — | EP | disclosed |
| EP-1375483-A1 | 6-CHLORO-3-PYRIDYLMETHYLPROPYLAMINE DERIVATIVES, PREPARATION PROCESS THEREOF AND BACTERICIDES | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 2004-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059703-A1 | Treating, ameliorating, preventing, or modulating restenosis following angioplastic surgery, injure the vascular system; a salt of N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea; intravascular stent is impregnated with the compound to inhibit restenosis | PDGFRB, PDGFRA, PDGFA | KIF11 4335/4885 |
| US-20040235829-A1 | Novel cyanopyridine derivatives useful in the treatment of cancer and other disorders | VHL, HCCS, CDK4 | KIF11 3786/4885 |
| US-20040152903-A1 | 6-chloro-3-pyridylmethylpropylamine derivatives, preparation process thereof and bactericides | PGLS, TLR6, UROD | KIF11 3647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.